Hematol Oncol Clin North Am. 2021 Apr;35(2):391-407. doi: 10.1016/j.hoc.2020.12.004. Epub 2021 Feb 3.
ABSTRACT
Myelofibrosis (MF) belongs to a group of clonal stem cell disorders known as the BCR-ABL-negative myeloproliferative neoplasms. Allogeneic hematopoietic stem cell transplantation (HCT) is currently the only curative treatment option for MF. Because HCT can be associated with significant morbidity and mortality, patients need to be carefully selected based on disease-risk, fitness, and transplant factors. Furthermore, in the era of JAK inhibitors, the timing of transplantation has become a challenging question. Here the authors review recent developments in HCT for MF, focusing on risk stratification and optimal timing.
PMID:33641876 | DOI:10.1016/j.hoc.2020.12.004